Ascendis Pharma presented the two‑year data from its pivotal ApproaCH trial for TransCon CNP (navepegritide) at the ACMG 2026 meeting. The study, which enrolled 84 children aged 2‑11, shows that those treated with the once‑weekly therapy maintained consistent linear growth through week 104 and achieved further improvements in body proportionality during the second year of treatment.
The trial results confirm that children who switched from placebo to TransCon CNP at week 52 achieved one‑year outcomes comparable to the original randomized controlled phase. Dr. Ravi Savarirayan, a presenter of the data, noted, "Two-year data from the ApproaCH Trial demonstrated continued improvement in body proportionality and sustained increases in linear growth," and added, "children switching from placebo to TransCon CNP at Week 52 demonstrated one-year results that mirrored those previously reported in three randomized double‑blind, placebo‑controlled trials of TransCon CNP, highlighting its potential as a transformative once‑weekly treatment option for children with achondroplasia."
The data reinforce the therapeutic value of TransCon CNP and support Ascendis’s ongoing regulatory strategy. The drug, marketed as YUVIWEL®, was approved by the U.S. FDA in February 2026 and is currently under review by the European Medicines Agency, with a decision expected in the fourth quarter of 2026. The sustained efficacy demonstrated in the two‑year study strengthens the company’s position as it seeks to expand its rare‑disease portfolio and leverage its TransCon technology platform.
Financially, Ascendis reported Q4 2025 earnings on February 11 2026, posting a net loss of €34 million (or €0.55 per share) compared with a €38 million loss (or €0.64 per share) in Q4 2024. Total revenue for Q4 2025 reached €248 million, up from €174 million in Q4 2024, driven by strong demand for its commercial products YORVIPATH and SKYTROFA. The positive clinical data for TransCon CNP are expected to further accelerate revenue growth and support the company’s path to cash‑flow positivity.
Analysts have responded to the announcement by raising price targets, with RBC Capital lifting its target to $275.00 and Wedbush to $273.00, reflecting confidence in Ascendis’s regulatory momentum and the commercial potential of YUVIWEL. The sustained efficacy data are likely to reinforce the company’s valuation narrative and support its broader pipeline strategy.
The two‑year ApproaCH trial results underscore Ascendis’s ability to deliver durable, once‑weekly therapy for achondroplasia, validate its platform technology, and strengthen its regulatory and commercial trajectory in the rare‑disease space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.